Pharma BD Deal Intelligence
Novo Nordisk A/S / Omeros Corporation
2025 · Asset Purchase · $2.1B · Complete
Novo Nordisk and Omeros announced a definitive asset purchase and license agreement giving Novo Nordisk exclusive global rights to zaltenibart (OMS906), a late-stage clinical humanized monoclonal antibody targeting MASP-3, the most upstream activator of the alternative complement pathway, in development for rare blood and kidney disorders. Omeros is eligible for $340 million in upfront and near-term milestone payments and up to $2.1 billion in total including development and commercial milestones, plus tiered royalties on net sales. The transaction closed December 1, 2025.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal.
Key facts
- Announced Oct 15, 2025
- Closed Dec 01, 2025
- Deal value $2.1B
- Deal type Asset Purchase
- Therapeutic area Hematology, Nephrology
- Indications Paroxysmal nocturnal hemoglobinuria and other complement-mediated blood and kidney disorders
- Key assets Zaltenibart (OMS906)
- Mechanism MASP-3 inhibitor (alternative complement pathway) humanized monoclonal antibody
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Novo Nordisk A/S deals · Hematology deals